{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-008141","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.908410+00:00","generated_at":"2026-06-21T11:00:38.342042+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CNS Pharmaceuticals prices $6.0M public offering of shares and warrants at $3.175/unit","bullets":["Gross proceeds ~$6.0M from sale of 1,889,764 units (share or pre-funded warrant + common warrant) at $3.175/unit.","Common warrants exercisable at $3.03 per share, expire 5 years from issuance; pre-funded warrants exercisable at $0.001 per share.","Existing warrants amended: exercise price reduced from $66/$24.60 to $3.03, expiration extended to 5 years after closing.","Offering expected to close Dec 5, 2022; net proceeds for ongoing clinical trial, R&D, and working capital.","H.C. Wainwright leads placement; Brookline Capital Markets co-placement; cash fee 7% of gross, plus placement agent warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-008141","json":"https://secwatch.observer/filing/0001683168-22-008141.json","markdown":"https://secwatch.observer/filing/0001683168-22-008141.md","text":"https://secwatch.observer/filing/0001683168-22-008141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/0001683168-22-008141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:00:38.342042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a29483b2b6b964c6294a8960332c9a327c2d4bf","claim":"CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with an institutional investor valued at approximately $6.0 million.","evidence_excerpt":"On November 30 2022, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor for the sale by the Company of (i) 147,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,742,764 shares of Common Stock and (iii) warrants to purchase up to an aggregate of 1,889,764 shares of Common Stock (the “Common Warrants” and, collectively with the Pre-Funded Warrants, the “Warrants”), in a public offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/0001683168-22-008141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"approximately $6.0 million"}],"fact_type":"material_agreement"},{"claim_id":"dedff53fe18603faf476abd068e650ede7fef7ec","claim":"CNS Pharmaceuticals, Inc. entered into Placement Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2022-11-30).","evidence_excerpt":"On November 30, 2022, the Company entered into a placement agency agreement with H.C. Wainwright & Co., LLC (“Wainwright”) and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline” and collectively with Wainright, the “Placement Agents”) (the “Placement Agreement”), pursuant to which the Company has agreed to pay the Placement Agents an aggregate fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the transaction.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316822008141/0001683168-22-008141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC"},{"label":"Effective","value":"2022-11-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}